Anúncio
Anúncio
NVCR
NovoCure Limited Ordinary Shares
14.31
USDPatrocinado
+0.02
+0.11%
07 de jan., 13:26 UTC -5
Abrir
Relatórios de Lucros NVCR
Rácio de surpresa positiva
NVCR separação 23 de 40 últimas estimativas.
57%
Próximo Relatório
Data do Próximo Relatório
23 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$172.30M
/-$0.40
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+3.05%
/+21.21%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+6.84%
/-34.43%
NovoCure Limited Ordinary Shares earnings per share and revenue
On 30 de out. de 2025, NVCR reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.42 USD, resulting in a 23.15% surprise. Revenue reached 167.20 milhão, compared to an expected 162.37 milhão, with a 2.98% difference. The market reacted with a -4.90% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analistas forecast an EPS of -0.40 USD, with revenue projected to reach 172.30 milhão USD, implying an aumentar of 21.21% EPS, and aumentar of 3.05% in Revenue from the last quarter.
FAQ
What were NovoCure Limited Ordinary Shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, NovoCure Limited Ordinary Shares reported EPS of -$0.33, beating estimates by 23.15%, and revenue of $167.20M, 2.98% above expectations.
How did the market react to NovoCure Limited Ordinary Shares's Q3 2025 earnings?
The stock price moved down -4.9%, changed from $13.48 before the earnings release to $12.82 the day after.
When is NovoCure Limited Ordinary Shares expected to report next?
The next earning report is scheduled for 23 de fev. de 2026.
What are the forecasts for NovoCure Limited Ordinary Shares's next earnings report?
Based on 10
analistas, NovoCure Limited Ordinary Shares is expected to report EPS of -$0.40 and revenue of $172.30M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio